it-901

IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with IC50 values for NF-κB and c-Rel binding to DNA of 0.1 µM and 3 µM, respectively. IT-901 is a naphthalene thiobarbiturate derivative with antitumor activity and is used for the prevention and treatment of human lymphoma and myeloma.

Talizumab (TNX 901) is a humanized IgG1 monoclonal antibody that specifically targets circulating immunoglobulin E (IgE). it binds to free IgE not already bound by the high-affinity IgE receptors (FcεRI) present on mast cells and basophils, which leads to the marked downregulation of these receptors and additionally inhibits allergen-specific T-cell activation by interfering with antigen processing and presentation activities.

Olintatug (ADCT-901) is a highly specialized antibody-drug conjugate (ADC) targeting Kidney-Associated Antigen 1 (KAAG1). It comprises a humanized monoclonal antibody conjugated to a potent pyrrolobenzodiazepine (PBD) dimer cytotoxin via a cathepsin-cleavable linker. Olintatug specifically binds to KAAG1 on tumor cell surfaces, internalizes, and releases the PBD dimer, which induces lethal DNA interstrand cross-links, blocking cell division. It is investigated for KAAG1-expressing solid tumors, including ovarian and triple-negative breast cancers.

PG-901 is a full and selective MC5R agonist, exhibiting an EC50 of 0.072 nM for hMC5R. It also acts as a complete antagonist for hMC3R and hMC4R, with Kb values of 1.0 nM and 0.53 nM, respectively. Additionally, PG-901 significantly reduces the levels of cytokines (IL-1α, IL-1β, and IL-6), enhances glucose tolerance, lowers blood sugar, and mitigates retinal damage.